Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Immunome, Inc.    IMNM

IMMUNOME, INC.

(IMNM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
14.18(c) 14.68(c) 17.85(c) 16.05(c) 15.34(c) Last
77 798 36 268 147 273 131 211 91 446 Volume
-6.83% +3.53% +21.59% -10.08% -4.42% Change
More quotes
Financials (USD)
Sales 2020 1,05 M - -
Net income 2020 -15,1 M - -
Net Debt 2020 - - -
P/E ratio 2020 -2,93x
Yield 2020 -
Sales 2021 5,58 M - -
Net income 2021 -19,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -10,5x
Yield 2021 -
Capitalization 162 M 162 M -
Capi. / Sales 2020 154x
Capi. / Sales 2021 29,0x
Nbr of Employees 21
Free-Float 75,0%
More Financials
Company
Immunome Inc. is a biopharmaceutical company utilizing its human memory B cell platform to discover and develop antibody therapeutics. The Company’s primary focus is oncology. Its discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery... 
More about the company
All news about IMMUNOME, INC.
2020IMMUNOME PROVIDES ORGANIZATIONAL UPD : Appoints Richard Baron to its Board of Di..
BU
2020IMMUNOME INC. : Change in Directors or Principal Officers, Financial Statements ..
AQ
2020IMMUNOME : Reports Third Quarter 2020 Financial Results and Significant Progress
BU
2020IMMUNOME INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
2020IMMUNOME : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2020IMMUNOME INC. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
2020IMMUNOME : Announces Exercise in Full and Closing of Over-Allotment Option in In..
BU
2020IMMUNOME INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,..
AQ
2020IMMUNOME : Announces Pricing of Upsized Initial Public Offering
BU
More news
News in other languages on IMMUNOME, INC.

- No features available -

More news
Chart IMMUNOME, INC.
Duration : Period :
Immunome, Inc. Technical Analysis Chart | IMNM | US45257U1088 | MarketScreener
Technical analysis trends IMMUNOME, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 23,00 $
Last Close Price 16,05 $
Spread / Highest target 74,5%
Spread / Average Target 43,3%
Spread / Lowest Target 12,1%
EPS Revisions
Managers and Directors
NameTitle
Purnanand D. Sarma President, Chief Executive Officer & Director
Michael Rapoport Chairman
Diane M. Marcou Chief Financial Officer
Michael J. Morin Chief Scientific Officer
Matthew K. Robinson Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOME, INC.65.81%169
GILEAD SCIENCES, INC.14.49%83 610
WUXI APPTEC CO., LTD.36.65%64 891
VERTEX PHARMACEUTICALS0.55%61 795
REGENERON PHARMACEUTICALS12.62%57 427
BEIGENE, LTD.38.68%32 675